FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161036119> ?p ?o ?g. }

• W2161036119 endingPage "3595" @default.
• W2161036119 startingPage "3588" @default.
• W2161036119 abstract "Purpose To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti–VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC). Patients and Methods HORIZON III [Cediranib Plus FOLFOX6 Versus Bevacizumab Plus FOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer] had an adaptive phase II/III design. Patients randomly assigned 1:1:1 received mFOLFOX6 [oxaliplatin 85 mg/m 2 and leucovorin 400 mg/m 2 intravenously followed by fluorouracil 400 mg/m 2 intravenously on day 1 and then continuous infusion of 2,400 mg/m 2 over the next 46 hours every 2 weeks] with cediranib (20 or 30 mg per day) or bevacizumab (5 mg/kg every 14 days). An independent end-of-phase II analysis concluded that mFOLFOX6/cediranib 20 mg met predefined criteria for continuation; subsequent patients received mFOLFOX6/cediranib 20 mg or mFOLFOX6/bevacizumab (randomly assigned 1:1). The primary objective was to compare progression-free survival (PFS). Results In all, 1,422 patients received mFOLFOX6/cediranib 20 mg (n = 709) or mFOLFOX6/bevacizumab (n = 713). Primary analysis revealed no significant difference between arms for PFS (hazard ratio [HR], 1.10; 95% CI, 0.97 to 1.25; P = .119), overall survival (OS; HR, 0.95; 95% CI, 0.82 to 1.10; P = .541), or overall response rate (46.3% v 47.3%). Median PFS and OS were 9.9 and 22.8 months for mFOLFOX6/cediranib and 10.3 and 21.3 months for mFOLFOX6/bevacizumab. The PFS upper 95% CI was outside the predefined noninferiority limit (HR < 1.2). Common adverse events with more than 5% incidence in the cediranib arm included diarrhea, neutropenia, and hypertension. Cediranib-treated patients completed fewer chemotherapy cycles than bevacizumab-treated patients (median 10 v 12 cycles). Patient-reported outcomes (PROs) were significantly less favorable in cediranib-treated versus bevacizumab-treated patients (P < .001). Conclusion Cediranib activity, in terms of PFS and OS, was comparable to that of bevacizumab when added to mFOLFOX6; however, the predefined boundary for PFS noninferiority was not met. The cediranib safety profile was consistent with previous studies but led to less favorable PROs compared with bevacizumab. Investigation of oral TKIs in CRC continues." @default.
• W2161036119 created "2016-06-24" @default.
• W2161036119 creator A5011308487 @default.
• W2161036119 creator A5012784092 @default.
• W2161036119 creator A5019547742 @default.
• W2161036119 creator A5033985179 @default.
• W2161036119 creator A5035175323 @default.
• W2161036119 creator A5039344852 @default.
• W2161036119 creator A5043926451 @default.
• W2161036119 creator A5045005527 @default.
• W2161036119 creator A5048312892 @default.
• W2161036119 creator A5052243751 @default.
• W2161036119 creator A5056345420 @default.
• W2161036119 creator A5068720728 @default.
• W2161036119 creator A5084791255 @default.
• W2161036119 creator A5090645179 @default.
• W2161036119 creator A5091058723 @default.
• W2161036119 date "2012-10-10" @default.
• W2161036119 modified "2023-10-18" @default.
• W2161036119 title "Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)" @default.
• W2161036119 cites W1971837077 @default.
• W2161036119 cites W1977614360 @default.
• W2161036119 cites W2017912212 @default.
• W2161036119 cites W2025967354 @default.
• W2161036119 cites W2031383612 @default.
• W2161036119 cites W2061515693 @default.
• W2161036119 cites W2078797757 @default.
• W2161036119 cites W2092215947 @default.
• W2161036119 cites W2096415778 @default.
• W2161036119 cites W2097373408 @default.
• W2161036119 cites W2098354753 @default.
• W2161036119 cites W2109240520 @default.
• W2161036119 cites W2113818241 @default.
• W2161036119 cites W2118971132 @default.
• W2161036119 cites W2125416423 @default.
• W2161036119 cites W2127179857 @default.
• W2161036119 cites W2129851137 @default.
• W2161036119 cites W2137758263 @default.
• W2161036119 cites W2140043667 @default.
• W2161036119 cites W2143278325 @default.
• W2161036119 cites W2143695921 @default.
• W2161036119 cites W2143743735 @default.
• W2161036119 cites W2152004983 @default.
• W2161036119 cites W2154056804 @default.
• W2161036119 cites W2157769714 @default.
• W2161036119 cites W2171046634 @default.
• W2161036119 cites W2478525303 @default.
• W2161036119 cites W2591385705 @default.
• W2161036119 doi "https://doi.org/10.1200/jco.2012.42.5355" @default.
• W2161036119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22965961" @default.
• W2161036119 hasPublicationYear "2012" @default.
• W2161036119 type Work @default.
• W2161036119 sameAs 2161036119 @default.
• W2161036119 citedByCount "183" @default.
• W2161036119 countsByYear W21610361192012 @default.
• W2161036119 countsByYear W21610361192013 @default.
• W2161036119 countsByYear W21610361192014 @default.
• W2161036119 countsByYear W21610361192015 @default.
• W2161036119 countsByYear W21610361192016 @default.
• W2161036119 countsByYear W21610361192017 @default.
• W2161036119 countsByYear W21610361192018 @default.
• W2161036119 countsByYear W21610361192019 @default.
• W2161036119 countsByYear W21610361192020 @default.
• W2161036119 countsByYear W21610361192021 @default.
• W2161036119 countsByYear W21610361192022 @default.
• W2161036119 countsByYear W21610361192023 @default.
• W2161036119 crossrefType "journal-article" @default.
• W2161036119 hasAuthorship W2161036119A5011308487 @default.
• W2161036119 hasAuthorship W2161036119A5012784092 @default.
• W2161036119 hasAuthorship W2161036119A5019547742 @default.
• W2161036119 hasAuthorship W2161036119A5033985179 @default.
• W2161036119 hasAuthorship W2161036119A5035175323 @default.
• W2161036119 hasAuthorship W2161036119A5039344852 @default.
• W2161036119 hasAuthorship W2161036119A5043926451 @default.
• W2161036119 hasAuthorship W2161036119A5045005527 @default.
• W2161036119 hasAuthorship W2161036119A5048312892 @default.
• W2161036119 hasAuthorship W2161036119A5052243751 @default.
• W2161036119 hasAuthorship W2161036119A5056345420 @default.
• W2161036119 hasAuthorship W2161036119A5068720728 @default.
• W2161036119 hasAuthorship W2161036119A5084791255 @default.
• W2161036119 hasAuthorship W2161036119A5090645179 @default.
• W2161036119 hasAuthorship W2161036119A5091058723 @default.
• W2161036119 hasBestOaLocation W21610361191 @default.
• W2161036119 hasConcept C121608353 @default.
• W2161036119 hasConcept C126322002 @default.
• W2161036119 hasConcept C143998085 @default.
• W2161036119 hasConcept C207103383 @default.
• W2161036119 hasConcept C2776694085 @default.
• W2161036119 hasConcept C2777802072 @default.
• W2161036119 hasConcept C2780456651 @default.
• W2161036119 hasConcept C2780739268 @default.
• W2161036119 hasConcept C2780962732 @default.
• W2161036119 hasConcept C44249647 @default.
• W2161036119 hasConcept C526805850 @default.
• W2161036119 hasConcept C71924100 @default.
• W2161036119 hasConcept C90924648 @default.
• W2161036119 hasConceptScore W2161036119C121608353 @default.
• W2161036119 hasConceptScore W2161036119C126322002 @default.

• next